SSRIs in pregnancy: small risk of birth defects?

December 2007
Archives of Disease in Childhood;Dec2007, Vol. 92 Issue 12, p1108
Academic Journal
The article discusses the therapeutic benefits and applications of selective serotonin-reuptake inhibitors (SSRI). These were introduced as a new class of antidepressant drugs in the late 1980s. Recently, there have been reports of increased risk of birth defects associated the use of some SSRI in early pregnancy and the risk is small. The use of SSRI overall in the first trimester was not associated with significantly increased risks of defects previously associated with SSRI use. Among individual SSRI there were significant associations between use of sertraline and risk of omphalocoel or septal defect, and use of paroxetine and risk of right ventricular outflow tract obstruction defects.


Related Articles

  • Inactivation of 5-HT2C Receptors Potentiates Consequences of Serotonin Reuptake Blockade. Cremers, Thomas I.F.H.; Giorgetti, Marco; Bosker, Fokko J.; Hogg, Sandra; Arnt, Jørn; Mørk, Arne; Honig, Gerard; Bøgesø, Klaus-Peter; Westerink, Ben H.C.; den Boer, Hans; Wikstrom, Håkan V.; Tecott, Laurence H. // Neuropsychopharmacology;Oct2004, Vol. 29 Issue 10, p1782 

    The enhancement of central serotonin system function underlies the therapeutic effects of selective serotonin reuptake inhibitors (SSRIs), which have become the most commonly used class of antidepressant agents. However, many individuals experience depressive episodes that are resistant to SSRI...

  • Antidepressants and risk of prostate cancer: a nested case – control study. Tamim, H. M.; Mahmud, S.; Hanley, J. A.; Boivin, J-F; Stang, M. R.; Collet, J-P // Prostate Cancer & Prostatic Diseases;2008, Vol. 11 Issue 1, p53 

    Although the association between antidepressant drug use and risk of cancer has received considerable attention in the past years, no work has been done specifically on prostate cancer. We carried out a population-based case – control study to assess the risk of prostate cancer in...

  • New SSRI alarm on the way.  // Pulse;2/19/2005, Vol. 65 Issue 7, p3 

    The article reports that general practitioners are bracing themselves for a new wave of patients alarmed over selective serotonin uptake inhibitors (SSRIs). In one study; researchers analyzed 702 trials of 87,000 patients and found those taking SSRIs were 2.28 times as likely to attempt suicide...

  • Bleeding gums: Duloxetine may be the cause. Balhara, Y. P. S.; Sagar, R.; Varghese, S. T. // Journal of Postgraduate Medicine;Jan-Mar2007, Vol. 53 Issue 1, p44 

    Duloxetine is a newly introduced drug. It is being prescribed for the management of diabetic neuropathic pain and major depressive disorder. The most frequently observed adverse events with duloxetine are nausea, dry mouth and somnolence, constipation, diarrhea, decreased appetite, weight loss,...

  • Forensic database study suggests selective serotonin reuptake inhibitors do not increase the risk of suicide in people taking antidepressants. Cipriani, Andrea // Evidence Based Mental Health;Nov2005, Vol. 8 Issue 4, p113 

    This article presents a study which found that selective serotonin reuptake inhibitors (SSRI) do not increase the risk of suicide in people taking antidepressants. In people taking antidepressants, SSRI use was no more common among people who had committed suicide than among those who had died...

  • Serotonin receptors: role in depression. Artigas, F. // Actas Espanolas de Psiquiatria;ene 2008 Supplement 1, Vol. 36, p28 

    The article focuses on the efficacy of selective serotonin reuptake inhibitors (SSRIs) in treating mental depression. It states that serotonergic neurons are comprised of two autoreceptors which includes the raphé nuclei and 5-HT axons. According to studies, the administration of SSRIs...

  • Fluoxetine, a Highly Selective Serotonin Reuptake Inhibitor: A Review of Preclinical Studies. Schmidt, Michael J.; Fuller, Ray W.; Wong, David T. // British Journal of Psychiatry;Sep88 Supplement, p40 

    The article reports on fluoxetine, a highly selective serotonin reuptake inhibitor. It is noted that the chemical structure of fluoxetine lacks the three-fused ring system contained in tricyclic antidepressant drugs like imipramine and amitriptyline. Fluoxetine has been established to be a...

  • The Evidence for 20 mg a day of Fluoxetine as the Optimal Dose in the Treatment of Depression. Altamura, A.C.; Montgomery, S.A.; Wernicke, J.F. // British Journal of Psychiatry;Sep88 Supplement, p109 

    The article reports on the use of fluoxetine in the treatment of depression. Fluoxetine, a selective serotonin-uptake inhibitor, has been established to be effective in the treatment of depression. Various studies have posited that this compound is more effective than placebo. This drug has also...

  • Detrimental Antidepressant Drug–Drug Interactions: Are They Clinically Relevant? Preskorn, Sheldon; Werder, Steve // Neuropsychopharmacology;Aug2006, Vol. 31 Issue 8, p1605 

    This paper takes the position that detrimental drug–drug interactions (DDIs) involving antidepressants are clinically relevant. In doing so, it begins with a definition of the terms: drug–drug interaction, detrimental, and clinical relevance. It then discusses the issues of proof...


Read the Article


Sorry, but this item is not currently available from your library.

Try another library?
Sign out of this library

Other Topics